


WHAT IS CLAIMED IS:

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein

Xaa₁ is absent or Xaa₁ is selected from the group consisting of hydrogen and an acyl group, wherein the acyl group is selected from the group consisting of

$\text{R}^1\text{-(CH}_2\text{)}_n\text{-C(O)-}$, wherein n is an integer from 0 to 8 and R¹ is selected from the group consisting of N-acetylamino, alkoxy, alkyl, aryl, carboxy, cycloalkenyl, cycloalkyl, heterocycle, hydroxy; and

$\text{R}^2\text{-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_p\text{-CH}_2\text{-C(O)-}$, wherein p is an integer from 1 to 8 and R² is selected from the group consisting of hydrogen, N-acetylamino, and alkyl;

Xaa₂ is an amino acyl residue selected from the group consisting of

alanyl,

β-alanyl,

asparaginylyl,

citrullyl,

N-ethylglycyl,

glutaminylyl,

glutamyl,

methionyl,

N-methylalanyl,

N-methylprolyl,

prolyl,

pyro-glutamyl,

sarcosyl,

seryl,

threonyl,

$\text{H}_3\text{C-C(O)-HN-(CH}_2\text{)}_q\text{-C(O)-}$, wherein q is an integer from 1 to 8, and

$\text{H}_3\text{C-C(O)-HN-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_r\text{-CH}_2\text{-C(O)-}$, wherein r is an integer from 1 to 8;

with the proviso that Xaa₁ is absent when Xaa₂ is N-methylprolyl, $\text{H}_3\text{C-C(O)-HN-(CH}_2\text{)}_q\text{-C(O)-}$, or $\text{H}_3\text{C-C(O)-HN-CH}_2\text{CH}_2\text{-O-(CH}_2\text{CH}_2\text{O)}_r\text{-CH}_2\text{-C(O)-}$;

Xaa₃ is an amino acyl residue selected from the group consisting of

alanyl,
asparaginylyl,
aspartyl,
glutaminylyl,
glutamyl,
glycyl,
leucyl,
methionyl,
phenylalanyl,
prolyl, and
seryl;

Xaa₄ is an amino acyl residue selected from the group consisting of

alloisoleucyl,
allylglycyl,
2-aminobutyryl,
(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
aspartyl,
3-(5-bromothiophen-2-yl)alanyl,
3-(3-chlorophenyl)alanyl,
3-(4-chlorophenyl)alanyl,
3-(3-cyanophenyl)alanyl,
cysteinyl(S-ethyl),
cysteinyl(S-methyl),
2,4-diaminobutanoyl,
2,3-diaminopropionyl,
3-(3,4-dimethoxyphenyl)alanyl,
3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
histidyl,
homophenylalanyl,
homoseryl,
lysyl(N-epsilon-acetyl),
methionyl(sulfone),
methionyl(sulfoxide),

75

3-(4-methylphenyl)alanyl,

3-(naphth-1-yl)alanyl,

3-(naphth-2-yl)alanyl,

ornithyl,

phenylglycyl,

prolyl,

3-(3-pyridyl)alanyl,

80

seryl(benzyl),

styrylalanyl,

1,2,3,4-tetrahydroisoquinoline-3-carbonyl,

3-(thiazolyl)alanyl,

3-(thien-2-yl)alanyl,

85

D-3-(thien-2-yl)alanyl,

tryptyl,

tyrosyl, and

D-valyl;

90

Xaa₅ is an amino acyl residue selected from the group consisting of

D-alanyl,

alloisoleucyl,

D-alloisoleucyl,

D-allothreonyl,

95

D-allylglycyl,

D-2-aminobutyryl,

D-3-(4-aminophenyl)alanyl,

D-asparaginyll,

D-aspartyl,

100

D-3-(4,4'-biphenyl)alanyl,

D-*t*-butylglycyl,

D-3-(4-chlorophenyl)alanyl,

D-citrullyl,

D-3-(3-cyanophenyl)alanyl,

105

D-cyclohexylalanyl,

D-cyclohexylglycyl,

D-cysteinyll,

D-cysteinyll(S-*t*-butyl),

110

115

120

125

130

135

140

145

D-threonyl(O-benzyl),
D-3-(3-trifluoromethylphenyl)alanyl,
D-3-(3,4,5-trifluorophenyl)alanyl,

150

D-tryptyl,
D-tyrosyl(O-benzyl),
D-tyrosyl(O-ethyl),
D-tyrosyl, and
D-valyl;

155

Xaa₆ is an amino acyl residue selected from the group consisting of

160

alanyl,
allothreonyl,
D-allothreonyl,
allylglycyl,
asparaginyl,

165

cysteinyl,
glutaminyl,
glycyl,
histidyl,
homoseryl,
D-homoseryl,
3-(4-hydroxymethylphenyl)alanyl,

170

isoleucyl,
lysyl(N-epsilon-acetyl),
methionyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
norvalyl,

175

octylglycyl,
ornithyl,
penicillaminyl,
prolyl,
3-(3-pyridyl)alanyl,
seryl,

180

D-seryl,
threonyl,

D-threonyl,
tryptyl, and
tyrosyl;

185 Xaa₇ is an amino acyl residue selected from the group consisting of
alanyl,
allylglycyl,
2-aminobutyryl,
arginyl,
190 asparaginy, aspartyl,
3-(4-carboxyamidophenyl)alanyl,
citrullyl,
cyclohexylalanyl,
195 cysteiny, glutaminy,
D-glutaminy,
glutamyl,
glycyl,
200 histidyl,
homoalanyl,
homoleucyl,
homoseryl,
D-homoseryl,
205 isoleucyl,
leucyl,
D-leucyl,
lysyl(N-epsilon-acetyl),
lysyl(N-epsilon-isopropyl),
210 methionyl(sulfone),
methionyl(sulfoxide),
methionyl,
3-(naphth-1-yl)alanyl,
D-3-(naphth-1-yl)alanyl,
215 3-(naphth-2-yl)alanyl,
D-3-(naphth-2-yl)alanyl,

220

norleucyl,
norvalyl,
D-norvalyl,
octylglycyl,
penicillaminyl,
phenylalanyl,
propargylglycyl,
3-(3-pyridyl)alanyl,

225

seryl,
D-seryl,
threonyl,
tryptyl,
tyrosyl, and
valyl;

230

Xaa₈ is an amino acyl residue selected from the group consisting of

alanyl,
alloisoleucyl,
D-alloisoleucyl,
allylglycyl,
aspartyl,
t-butylglycyl,
citrullyl,

235

cyclohexylglycyl,
cysteinyl,
glutamyl,
glycyl,

240

homoseryl,

245

isoleucyl,
D-isoleucyl,
leucyl,

lysyl(N-epsilon-acetyl),
methionyl,

250

3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
norvalyl,

255

penicillaminyl,
phenylalanyl,
prolyl,
seryl,
tryptyl,
tyrosyl, and
valyl;

260

Xaa₉ is an amino acyl residue selected from
[(4-amino(N-isopropyl)methyl)phenyl]alanyl,
3-(4-amino-N-isopropylphenyl)alanyl,
arginyl,
arginyl(N^GN^Gdiethyl),
citrullyl,
3-(cyclohexyl)alanyl(4-N-isopropyl),
glycyl[4-piperidinyl(N-amidino)],
(3-guanidino)alanyl,
3-(4-guanidinophenyl)alanyl,
histidyl,
homoarginyl,
lysyl,
lysyl(N-epsilon-isopropyl),
lysyl(N-epsilon-nicotinyl),
norarginyl,
ornithyl(N-delta-isopropyl),
ornithyl(N-delta-nicotinyl),
ornithyl[N-delta-(2-imidazolyl)],
[4-piperidinyl(N-amidino)]alanyl, and
[3-pyrrolidinyl(2-N-amidino)]alanyl;

265

270

275

280

Xaa₁₀ is an amino acyl residue selected from the group consisting of

285

D-alanyl,
2-aminobutyryl,
2-aminoisobutyryl,
t-butylglycyl,
homoprolyl,

hydroxypropyl,

290

isoleucyl,

leucyl,

phenylalanyl,

prolyl,

D-prolyl,

295

seryl,

1,2,3,4-tetrahydroisoquinoline-3-carbonyl,

threonyl, and

valyl;

300

Xaa₁₁ is a hydroxy group or an amino acid amide selected from the group consisting of

D-alanylamide,

D-alanylethylamide,

azaglycylamide,

305

glycylamide,

glycylethylamide,


sarcosylamide,

serylamide,

D-serylamide,

310

a residue represented by the formula



a group represented by the formula -NH-R^5 ; wherein

s is an integer selected from 0 to 8;

R³ is selected from the group consisting of hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

315

R⁴ is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy;

provided that s is not zero when R⁴ is hydroxy or alkoxy; and

R⁵ is selected from hydrogen, hydroxy, and cycloalkyl.

320

2. A compound according to Claim 1, wherein Xaa₁ is absent or is selected from the group consisting of
hydrogen,

5 acetyl,
N-acetyl- β -alanyl,
(4-N-acetylamino)butyryl,
(6-N-acetylamino)caproyl,
(8-N-acetylamino)-3,6-dioxo-octanoyl,
butyryl,
10 caproyl,
5-chloro-2-hydroxynicotinyl,
5-chloro-6-hydroxynicotinyl,
2-chloroisonicotinyl,
2-chloro-6-methylnicotinyl,
15 cyclohexylacetyl,
furoyl,
2-hydroxy-6-methylnicotinyl,
6-hydroxynicotinyl,
6-hydroxy-2-picolinyl,
20 isonicotinyl,
2-methoxyacetyl,
2-methylnicotinyl,
6-methylnicotinyl,
(4-methyl)phenylacetyl,
25 nicotinyl,
phenylacetyl,
propionyl,
shikimyl,
succinyl, and
30 tetrahydrofuroyl.

3. A compound according to Claim 2 wherein Xaa₁ is selected from the group consisting of

acetyl, and
6-methylnicotinyl.

5

4. A compound according to Claim 1 wherein Xaa₂ is selected from the group consisting of

alanyl,

5 β -alanyl,
 asparaginylyl,
 citrullyl,
 N-ethylglycyl,
 glutaminylyl,
 glutamyl,
 10 methionyl,
 N-methylalanyl,
 N-methylprolyl,
 prolyl,
 pyro-glutamyl,
 15 sarcosyl,
 seryl,
 threonyl,
 $\text{H}_3\text{C}-\text{C}(\text{O})-\text{HN}-(\text{CH}_2)_q-\text{C}(\text{O})-$, wherein q is an integer from 1 to 8, and
 $\text{H}_3\text{C}-\text{C}(\text{O})-\text{HN}-\text{CH}_2\text{CH}_2-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_r-\text{CH}_2-\text{C}(\text{O})-$, wherein r is an integer
 20 from 1 to 8.

5. A compound according to Claim 4, wherein Xaa₂ is sarcosyl.

6. The compound according to Claim 1 wherein Xaa₃ is selected from the group consisting of

 alanyl,
 asparaginylyl,
 5 aspartyl,
 glutaminylyl,
 glutamyl,
 glycyl,
 leucyl,
 10 methionyl,
 phenylalanyl,
 prolyl, and
 seryl.

7. A compound according to Claim 6 wherein Xaa₃ is glycyl.

8. A compound according to Claim 1 wherein Xaa₄ is selected from the group consisting of

alloisoleucyl,
allylglycyl,
5 2-aminobutyryl,
(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
aspartyl,
3-(5-bromothien-2-yl)alanyl,
3-(3-chlorophenyl)alanyl,
10 3-(4-chlorophenyl)alanyl,
3-(3-cyanophenyl)alanyl,
cysteinyl(S-ethyl),
cysteinyl(S-methyl),
2,4-diaminobutanoyl,
15 2,3-diaminopropionyl,
3-(3,4-dimethoxyphenyl)alanyl,
3-(3-fluorophenyl)alanyl,
3-(4-fluorophenyl)alanyl,
histidyl,
20 homophenylalanyl,
homoseryl,
lysyl(N-epsilon-acetyl),
methionyl(sulfone),
methionyl(sulfoxide),
25 3-(4-methylphenyl)alanyl,
3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
ornithyl,
phenylglycyl,
30 prolyl,
3-(3-pyridyl)alanyl,
seryl(O-benzyl),
styrylalanyl,
1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
35 3-(thiazolyl)alanyl,
3-(thien-2-yl)alanyl,

40 D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
D-valyl.

9. A compound according to Claim 8 wherein Xaa₄ is selected from the group consisting of

5 alloisoleucyl,
 allylglycyl,
 2-aminobutyryl,
 (1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,
 3-(5-bromothien-2-yl)alanyl,
 3-(3-chlorophenyl)alanyl,
 3-(4-chlorophenyl)alanyl,
10 3-(3-cyanophenyl)alanyl,
 cysteinyl(S-ethyl),
 cysteinyl(S-methyl),
 2,4-diaminobutanoyl,
 2,3-diaminopropionyl,
15 3-(3,4-dimethoxyphenyl)alanyl,
 3-(3-fluorophenyl)alanyl,
 3-(4-fluorophenyl)alanyl,
 histidyl,
 homophenylalanyl,
20 homoseryl,
 lysyl(N-epsilon-acetyl),
 methionyl(sulfone),
 methionyl(sulfoxide),
 3-(4-methylphenyl)alanyl,
25 3-(naphth-1-yl)alanyl,
 3-(naphth-2-yl)alanyl,
 ornithyl,
 phenylglycyl,
 prolyl,
30 3-(3-pyridyl)alanyl,
 seryl(O-benzyl),

D-homoisoleucyl,
D-homophenylalanyl,
30 D-homoseryl,
isoleucyl,
D-isoleucyl,
D-leucyl,
D-lysyl,
35 D-lysyl(N-epsilon-nicotinyl),
D-methionyl,
D-3-(4-methylphenyl)alanyl,
D-3-(naphth-1-yl)alanyl,
D-3-(naphth-2-yl)alanyl,
40 D-neopentylglycyl,
D-3-(4-nitrophenyl)alanyl,
D-norleucyl,
D-norvalyl,
D-ornithyl,
45 D-penicillaminyl,
D-penicillaminyl(S-acetamidomethyl),
D-penicillaminyl(S-benzyl),
D-penicillaminyl(S-methyl),
D-phenylalanyl,
50 prolyl,
D-prolyl,
D-3-(3-pyridyl)alanyl,
D-seryl,
D-seryl(O-benzyl),
55 D-3-(thien-2-yl)alanyl,
D-threonyl,
D-threonyl(O-benzyl),
D-3-(3-trifluoromethylphenyl)alanyl,
D-3-(3,4,5-trifluorophenyl)alanyl,
60 D-tryptyl,
D-tyrosyl(O-benzyl),
D-tyrosyl(O-ethyl),
D-tyrosyl, and

D-valyl.

65

11. A compound according to Claim 10 wherein Xaa₅ is selected from the group consisting of

isoleucyl,

D-isoleucyl, and

5

D-leucyl.

12. A compound according to Claim 1 wherein Xaa₆ is selected from the group consisting of

alanyl,

allothreonyl,

5

D-allothreonyl,

allylglycyl,

asparaginy,

cysteinyl,

glutaminyl,

10

glycyl,

histidyl,

homoseryl,

D-homoseryl,

3-(4-hydroxymethylphenyl)alanyl,

15

isoleucyl,

lysyl(N-epsilon-acetyl),

methionyl,

3-(naphth-1-yl)alanyl,

3-(naphth-2-yl)alanyl,

20

norvalyl,

octylglycyl,

ornithyl,

penicillaminy,

prolyl,

25

3-(3-pyridyl)alanyl,

seryl,

D-seryl,

threonyl,

09718591.112200

30

D-threonyl,
tryptyl, and
tyrosyl.

13. A compound according to Claim 12 wherein Xaa₆ is selected from the group consisting of

seryl, and
threonyl.

5

14. A compound according to Claim 1 wherein Xaa₇ is selected from the group consisting of

alanyl,
allylglycyl,
2-aminobutyryl,
arginyl,
asparaginyll,
aspartyl,
3-(4-carboxyamidophenyl)alanyl,
citrullyl,
cyclohexylalanyl,
cysteinyll,
glutaminyl,
D-glutaminyl,
glutamyl,
glycyl,
histidyl,
homoalanyl,
homoleucyl,
homoseryl,
D-homoseryl,
isoleucyl,
leucyl,
D-leucyl,
lysyl(N-epsilon-acetyl),
lysyl(N-epsilon-isopropyl),
methionyl(sulfone),

5

10

15

20

25

002277 1659 112200



002277-16987460

methionyl(sulfoxide),
methionyl,
30 3-(naphth-1-yl)alanyl,
D-3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
D-3-(naphth-2-yl)alanyl,
norleucyl,
35 norvalyl,
D-norvalyl,
octylglycyl,
penicillaminyl,
phenylalanyl,
40 propargylglycyl,
3-(3-pyridyl)alanyl,
seryl,
D-seryl,
threonyl,
45 tryptyl,
tyrosyl, and
valyl.

15. A compound according to Claim 14 wherein Xaa₇ is selected from the group consisting of

glutaminyl,
norvalyl, and
5 seryl.

16. A compound according to Claim 1 wherein Xaa₈ is selected from the group consisting of

alanyl,
alloisoleucyl,
5 D-alloisoleucyl,
allylglycyl,
aspartyl,
t-butylglycyl,
citrullyl,

10 cyclohexylglycyl,
cysteinyl,
glutamyl,
glycyl,
homoseryl,
15 isoleucyl,
D-isoleucyl,
leucyl,
lysyl(N-epsilon-acetyl),
methionyl,
20 3-(naphth-1-yl)alanyl,
3-(naphth-2-yl)alanyl,
norvalyl,
penicillaminy,
phenylalanyl,
25 prolyl,
seryl,
tryptyl,
tyrosyl, and
valyl.

30

17. A compound according to Claim 16 wherein Xaa₈ is isoleucyl.

18. A compound according to Claim 1 wherein Xaa₉ is selected from the group consisting of

[(4-amino(N-isopropyl)methyl)phenyl]alanyl,
3-(4-amino-N-isopropylphenyl)alanyl,
5 arginyl,
arginyl(N^GN^{G'}diethyl),
citrullyl,
3-(cyclohexyl)alanyl(4-N-isopropyl),
glycyl[4-piperidiny(N-amidino)],
10 (3-guanidino)alanyl,
3-(4-guanidinophenyl)alanyl,
histidyl,
homoarginyl,

lysyl,
15 lysyl(N-epsilon-isopropyl),
lysyl(N-epsilon-nicotinyl),
norarginyl,
ornithyl(N-delta-isopropyl),
ornithyl(N-delta-nicotinyl),
20 ornithyl[N-delta-(2-imidazoliny)],
[4-piperidinyl(N-amidino)]alanyl, and
[3-pyrrolidinyl(2-N-amidino)]alanyl.

19. A compound according to Claim 18 wherein Xaa₉ is arginyl.

20. A compound according to Claim 1 wherein Xaa₁₀ is selected from the group consisting of

D-alanyl,
2-aminobutyryl,
5 2-aminoisobutyryl,
t-butylglycyl,
homopropyl,
hydroxypropyl,
isoleucyl,
10 leucyl,
phenylalanyl,
prolyl,
D-prolyl,
seryl,
15 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
threonyl, and
valyl.

21. A compound according to Claim 20 wherein Xaa₁₀ is prolyl.

22. A compound according to Claim 1 wherein Xaa₁₁ is selected from the group consisting of

D-alanylamine,
D-alanylethylamine,

5 azaglycylamide,
NH-cyclobutyl,
NH-cycloheptyl,
NH-1-(cyclohexyl)ethyl,
NH-2-(cyclohexyl)ethyl,
10 NH-2-(ethoxy)ethyl,
NH-ethyl,
glycylamide,
glycylethylamide,
NH-hexyl,
15 NH-2-(hydroxy)ethyl,
NH-isoamyl,
NH-isobutyl,
NH-2-(isopropoxy)ethyl,
NH-isopropyl,
20 NH-2-(methoxy)ethyl,
NH-3-(methoxy)propyl,
NH-propyl,
NH-2-(1-pyrrolidine)ethyl,
sarcosylamide,
25 serylamine, and
D-serylamine.

23. A compound according to Claim 22 wherein Xaa₁₁ is selected from the group consisting of

D-alanylamine, and
NH-ethyl.

5 24. A compound according to Claim 1 wherein

Xaa₁ is selected from the group consisting of
acetyl, and

5 6-methylnicotinyl;

Xaa₂ is sarcosyl;

Xaa₃ is glycyl;

Xaa₄ is selected from the group consisting of

alloisoleucyl,

allylglycyl,

2-aminobutyryl,

(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,

3-(5-bromothiophen-2-yl)alanyl,

3-(3-chlorophenyl)alanyl,

3-(4-chlorophenyl)alanyl,

3-(3-cyanophenyl)alanyl,

cysteinyl(S-ethyl),

cysteinyl(S-methyl),

2,3-diaminopropionyl,

2,4-diaminobutanoyl,

3-(3,4-dimethoxyphenyl)alanyl,

3-(3-fluorophenyl)alanyl,

3-(4-fluorophenyl)alanyl,

histidyl,

homophenylalanyl,

homoseryl,

lysyl(N-epsilon-acetyl),

methionyl(sulfone),

methionyl(sulfoxide),

3-(4-methylphenyl)alanyl,

3-(naphth-1-yl)alanyl,

3-(naphth-2-yl)alanyl,

ornithyl,

phenylglycyl,

prolyl,

3-(3-pyridyl)alanyl,

seryl(O-benzyl),

styrylalanyl,

1,2,3,4-tetrahydroisoquinoline-3-carbonyl,

3-(thiazolyl)alanyl,

3-(thien-2-yl)alanyl,

45

D-3-(thien-2-yl)alanyl,
tryptyl,
tyrosyl, and
D-valyl,

50

Xaa₅ is selected from the group consisting of
isoleucyl,
D-isoleucyl, and
D-leucyl;

55

Xaa₆ is selected from the group consisting of
seryl, and
threonyl;

60

Xaa₇ is selected from the group consisting of
glutaminyl,
norvalyl, and
seryl;

65

Xaa₈ is isoleucyl;

Xaa₉ is arginyl;

Xaa₁₀ is prolyl; and

70

Xaa₁₁ is selected from the group consisting of
D-alanylamide, and
NH-ethyl.

25. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

26. A method of treating a patient in need of anti-angiogenesis therapy comprising administering to the patient in need a therapeutically effective amount of a compound of Claim 1.

27. A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration and diabetic retinopathy comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

5

28. A method of isolating a receptor from an endothelial cell comprising binding a compound of Claim 1 to the receptor to form a peptide receptor complex; isolating the peptide receptor complex; and purifying the receptor.

29. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-5-BrThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-2-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

5 N-Ac-Sar-Gly-Orn-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-4-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-HPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Me)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl, and

10 N-Ac-Sar-Gly-Tyr-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl.

30. A compound, or a therapeutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Pro-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

5 N-Ac-Sar-Gly-3-CNPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Cys(Et)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-4-ThzAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-3,4-diOMePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

10 N-Ac-Sar-Gly-4-MePheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-3-ClPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-PheGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-2,4-Diabu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

15 N-Ac-Sar-Gly-Met(O₂)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-1-Nal-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,

002211-16581260

- N-Ac-Sar-Gly-2-Abu-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-Met(O)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-His-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 20 N-Ac-Sar-Gly-Trp-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-Tic-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-StyAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-AllylGly-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-4-FPheAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 25 N-Ac-Sar-Gly-2,3-Diapr-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-Met(O₂)-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl
 N-Ac-Sar-Gly-3-PyrAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-4-ClPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-1-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl
 30 N-Ac-Sar-Gly-2-Nal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-3-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-HPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-4-FPheAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-alloIle-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 35 N-Ac-Sar-Gly-Ser(Bzl)-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-HSer-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Ser-Ser-Ile-Arg-ProNH-ethyl,
 N-6MeNic-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,
 40 N-Ac-Sar-Gly-3-CNPhe-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
 N-Ac-Sar-Gly-D-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,
 N-Ac-Sar-Gly-D-2-ThiAla-D-Leu-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
 N-Ac-Sar-Gly-(1R,4S)-AmCyeCO-D-Leu-Thr-Gln-Ile-Arg-ProNH-ethyl, and
 N-Ac-Sar-Gly-D-Val-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl.